## Summary
ProtEx is a retrieval-augmented protein function prediction method that, for each query sequence and candidate label, retrieves positive and negative exemplars (via BLAST or a BLAST-like local-alignment retriever) and feeds them along with the query to a T5 encoder-decoder, which outputs a binary score. The authors introduce a multi-sequence pretraining objective (masked-residue + bucketed Levenshtein similarity over UniRef90 sequence pairs) and report SOTA results across EC, GO, and Pfam splits, including the PDB-EC benchmark where they outperform 15B-parameter ESM-2 and structure-based models, with particularly strong gains on rare Pfam families.

## Strengths
- **Genuinely strong PDB-EC result**: ProtEx outperforms a 15B-parameter ESM-2, ESM-GearNet, PST, and structure-based models (Table 4). Notably, a properly thresholded BLAST baseline already beats most prior neural methods (0.900 at 95% identity), and ProtEx adds a further increment (0.909). This is a useful empirical finding for the field.
- **Pfam rare-class robustness is the most convincing evidence in the paper**: Figure 5 shows ProtEx maintaining ~90% family accuracy on families with 1–17 training examples while ProTNN/ProtENN drop substantially. Table 5 reports 92.6% family accuracy vs. 89.7% for the strongest prior ensemble, with the avg per-family accuracy jumping from 85.0 → 91.7.
- **Exemplar ablations are meaningful on Pfam and clustered GO**: family accuracy drops from 92.6 → 76.3 (Pfam) and 0.854 → 0.754 (clustered GO) without exemplars, supporting the retrieval-augmentation claim in those settings.
- **Exemplar-sampling analysis (Figure 6) is clean and practical**: uniform-sampling at training time better matches the Pfam evaluation similarity distribution (<25% identity), improving dev family accuracy from 89.39 → 91.85.
- **Inclusion of a properly thresholded BLAST baseline across all settings** is a service to the field; the paper makes the honest point that BLAST often beats more elaborate neural methods.

## Weaknesses

### Fatal
None.

### Major
- **Table 3 ablation contradicts the headline narrative.** On NEW-392 and Price-149 — the only EC settings where ProtEx massively beats CLEAN/BLAST (0.788/0.691 → 0.932/0.842) — the "no exemplars" variant scores 0.926 / 0.839, essentially identical to the full model. Whatever produces those large gains over CLEAN/BLAST is *not* exemplar conditioning. The paper nevertheless writes "ablating exemplars leads to a drop in performance" (§4.3), which is technically true (~0.6 / 0.3 points) but misleading given how the result is framed throughout the abstract and §1. Either the candidate-label filtering / pretraining is doing the heavy lifting here, or there is a confound; the paper does not engage with this.
- **The Pfam "no exemplar" baseline is not a clean ablation.** §4.4 / Appendix C.4.2 admits the no-exemplar Pfam baseline switches from binary classification to label-string generation because the binary head "generalizes poorly when the number of classes is large." The 92.6 → 76.3 gap therefore conflates absence of exemplars with a different prediction head and training procedure. The paper does acknowledge this, but it means the most dramatic exemplar-ablation in the paper cannot cleanly attribute the gap to exemplars.

### Minor
- **Sub-1-point F1 gains over BLAST on Sanderson EC/GO** (e.g., EC Random 0.984 → 0.987; GO Random 0.902 → 0.917; EC Clustered 0.950 → 0.958) are statistically significant (p<0.01 per Appendix C.1) but small relative to BLAST, which is essentially "free" compared to running an encoder-decoder up to |L̂_x| times per sequence. The paper acknowledges compute in §5 but does not quantify per-query latency/FLOPs vs. BLAST on these splits.
- **Pretraining-objective ablation has thin margins**: Table 7 shows sequence-pair-with-score 0.958 vs. sequence-pair 0.956 vs. single-sequence 0.952 (no-pretrain is meaningfully lower at 0.912). The similarity-score component — the genuinely novel part — contributes only 0.002 F1 on a single split with no variance reported. The pretraining objective is framed as central in the abstract; the data support that pretraining helps, not that the *score-prediction* novelty matters.
- **Candidate-label recall is not measured.** Because L̂_x is the union of labels on BLAST's top-100 neighbors, ProtEx's recall is upper-bounded by BLAST's. The paper motivates "dark matter" but never reports candidate-label recall for clustered GO/Pfam, which would quantify the headroom.
- **Unseen-label evaluation is modest**: 10% random label dropout (Table 6) leaves most of each class's annotated sequences in the retrieval index. Gains over BLAST on unseen classes are 0.964 → 0.970 (EC) and 0.816 → 0.839 (GO) — real but small.
- **Pfam retrieval pipeline is different from EC/GO** (per-class random sampling + local-alignment scoring rather than BLAST). This is documented in Appendix B.5 and is reasonable for scale, but it makes the Pfam result less directly comparable to other settings and entangles retriever change with exemplar effects.

### Trivial
- The "GO with ~31k classes" setting uses a single global threshold and reports Max-F1, sweeping the threshold post-hoc. A class-calibration analysis would strengthen the result.

## Nice-to-Haves
- A clean Pfam exemplar ablation using the same binary-classification head (e.g., restricted to candidates from the alternative retriever).
- Case studies where exemplar conditioning flips a BLAST error — especially via negative exemplars — to substantiate the claimed mechanism.
- A structure-based retriever (e.g., Foldseek) configuration, since BLAST's reach bounds ProtEx's reach. The paper notes this in §5.
- Variance / multi-seed numbers for Table 7 to substantiate the pretraining-objective claim.

## Removed Points
These points are flagged to be removed; treat them with caution.

- *(Harsh critic) "PDB-EC discussion overclaims by framing as outperforming ESM-2/structure models when BLAST already beats them."* The paper actually says exactly that — "BLAST with an alignment score threshold achieves a very competitive result on this setting." The honest framing the critic asks for is already present (§4.3).
- *(Strength finder) Generic "the evaluation protocol is exceptionally thorough."* Too generic; subsumed by the concrete strengths above.
- *(Strength finder) "Ablating exemplars causes substantial performance drops" as a global claim.* True for clustered GO and Pfam, false for NEW-392/Price-149 — the strength is partially in conflict with a verified weakness, so the unrestricted form is dropped.
- *Significance concerns about Sanderson EC/GO gains.* Appendix C.1 reports p<0.01; significance per se is not the issue, only effect size, which is captured under Minor.

## Novel Insights
None beyond the paper's own contributions. The paper's two real insights — that a properly thresholded BLAST baseline beats most published neural methods, and that retrieval-conditioned binary scoring scales gracefully to long-tail Pfam families — are valuable contributions the field should absorb.

## Suggestions
- Rewrite the contribution claim around what the ablations actually support: long-tail Pfam performance via per-class binary scoring with retrieved exemplars, and competitive PDB-EC results without structure. The current "exemplar conditioning drives the gains everywhere" framing does not match Table 3.
- Either explain the NEW-392 / Price-149 ablation or run a re-trained no-exemplar variant matching the full pipeline (same candidate-label filtering, same head) so the source of the +14 point gain over BLAST is isolated.
- Report candidate-label recall on clustered GO and Pfam to make the dependency on BLAST's reach explicit.
- Add multi-seed numbers to Table 7 so the pretraining-objective claim is supported by more than 0.002–0.006 F1 deltas.
- Quantify per-query cost vs. BLAST and CLEAN in §5.

## Evaluation
- *Originality*: moderate. Retrieval-augmented prediction is well-established in NLP; the novelty is the protein-pair pretraining + binary per-class scoring with positive/negative exemplars.
- *Importance*: protein function prediction is a high-value problem; the rare-class regime addressed is genuinely useful.
- *Claim support*: mixed. SOTA on PDB-EC and Pfam is well-supported; the central "exemplar conditioning drives the gains" claim is partially undermined by Table 3.
- *Soundness*: broadly sound, with the Pfam ablation confound and Table-3 narrative gap noted.
- *Clarity*: good. Method, datasets, and ablations are clearly written.
- *Value to community*: meaningful — both as a method and for the BLAST-baseline result.

## Calibration
- **jsQPjIaNNh** (5.25, Reject) — retrieval-based inter-protein similarity for function prediction. Topically the closest anchor; ProtEx has broader evaluation and SOTA on PDB-EC/Pfam beyond what this paper achieved → ProtEx should be above.
- **AK9uRqzLjt** (4.75, Reject) — LLaPA: LLM for EC prediction with retrieval. Similar idea space; ProtEx is more rigorously evaluated and shows larger effects → ProtEx above.
- **760br3YEtY** (5.60, Reject) — PEEP enzyme promiscuity prediction. Comparable scope; ProtEx is empirically stronger.
- **O0dW800ukz** (5.67, Reject) — ProteinSSA multimodal distillation. Comparable.
- **uQnvYP7yX9** (6.50, Accept) — ReNovo retrieval-based mass-spec peptide sequencing. Similar "retrieval helps on hard cases" story; ProtEx covers more downstream tasks but has weaker headline ablation cohesion than what likely accepted ReNovo.
- **22OTbutug9** (6.25, Accept) — RA-DIT retrieval-augmented LM. High-score retrieval-aug anchor.
- **jJCeMiwHdH** (7.00, Accept) — BioBridge multimodal biomedical foundation. Larger-scope contribution than ProtEx.
- **IEZjjDX0iC** (3.00, Reject) — PLM remote homology benchmarking, no novel claims. Far below ProtEx, which has clear method contribution.
- **vVlNBaiLdN** (3.00, Reject) — ESMGain modest fine-tuning gains. ProtEx clearly above.
- **PhanPLSHRt** (4.00, Reject) — EXCOST exemplar-contrastive with weak novelty.

ProtEx sits above the cluster of similar-topic mid-5 rejects (jsQPjIaNNh, 760br3YEtY, O0dW800ukz, AK9uRqzLjt) because it actually does establish SOTA on multiple benchmarks (notably PDB-EC over 15B ESM-2, Pfam rare-family accuracy), and below the 6.5+ accepts (ReNovo, RA-DIT, BioBridge) whose contributions are broader or more cohesive. The narrative–evidence mismatch in Table 3 and the Pfam ablation confound are real but do not invalidate the SOTA results. A 6.0 places it just above the topical mid-5 cluster but below the clear accepts.

MY FINAL SCORE: <pineapple>6.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>